Press Releases
AVITA Medical Establishes Proof of Concept for Novel Treatments Using Genetically-Modified Skin CellsData show promise for skin rejuvenation and treatment of epidermolysis bullosa
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced that preclinical data successfully established proof of concept in two key areas of cell-based gene therapy – skin rejuvenation and epidermolysis bullosa.
“We are very pleased to partner with leading scientists to explore opportunities for utilizing Spray-On Skin™ Cells in new and broad applications such as skin rejuvenation and genetic skin defects,” said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. “These data, while early, demonstrate promise for skin regeneration from modified Spray-On Skin™ Cells, for treatment of aging skin with reverse-aged skin cells and for treatment of epidermolysis bullosa with gene-corrected skin cells.”
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.67 |
Change
-0.028(1.62%) |
Mkt cap ! $123.3M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.74 | $1.67 | $584.9K | 345.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1413 | $1.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1310 | 3 |
View Market Depth
| Last trade - 14.28pm 19/09/2025 (20 minute delay) ? |
| AVH (ASX) Chart |